From its long-standing partner, Triphase Accelerator Corporation, Celgene has acquired its first asset, marizomib, which is being developed for multiple myeloma and glioma. Celgene is providing funding to Triphase for three ongoing clinical trials and will be responsible for the potential commercialisation of marizomib. The acquisition of this asset is an opportunity for Celgene to further bolster its position in multiple myeloma market as well as to foray into glioma which has a high unmet need.